Drug intelligence / Profile preview

HYG-440

Development stage: Preclinical
Lead developer: GLSynthesis
Modality: Small Molecules
Administration: Topical

Overview

HYG-440 is a topical "soft" anti-androgen developed by Hygeia Therapeutics (later acquired by RestorGenex Corporation). The drug was designed using a "soft drug" approach, meaning it is intended to be topically active at the site of application but rapidly metabolized into inactive metabolites upon entering the systemic circulation. This mechanism is designed to treat androgen-mediated dermatological conditions such as acne, hirsutism (excess facial hair), and androgenetic alopecia (hair loss) while minimizing systemic anti-androgenic side effects. The technology for HYG-440 was licensed from Yale University.

Other names: soft anti-androgen

Targets

AR (Adrenergic receptors)

Beyond the preview

Go deeper on HYG-440.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HYG-440.

Explore the full profile